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Abstract 
The new complexes [RuCl2(η
6-p-cymene)(κP-Ph2PR)] [R = 4-C6H4OSiMe2
tBu, 1; R = 4-C6H4Br, 2; R 
= OC(=O)CHCl2, 3; R = OPh, 4; R = O(2-C6H4SiMe2
tBu), 5] and [Ru(C2O4)(η
6-p-cymene){κP-
Ph2PO(2-C6H4(SiMe2
tBu))}], 6, were obtained in 83-98% yield from Ru(II) arene precursors by three 
different synthetic strategies. The unprecedented phosphine Ph2P(O(2-C6H4SiMe2
tBu)) was synthesized 
in 86% yield from 2-C6H4Br(OSiMe2
tBu) and Ph2PCl, via intramolecular oxygen to carbon 1,3 
migration of the silyl group (retro-Brook rearrangement). All the complexes were fully characterized 
by analytical and spectroscopic methods, and by single crystal X-ray diffraction in the cases of 3, 4, 5 
and 6. Complexes 1-6 and the model compounds [RuCl2(η
6-p-cymene)(κP-PPh3)] (Ru-PPh3) and 
[Ru(C2O4)(η
6-p-cymene)(κP-PPh3)] (Ru-PPh3-O) underwent slow degradation in chloroform solutions 
upon air contact; the mixed valence complex [(η6-p-cymene)Ru(µ-Cl)3RuCl2(κP-PPh3)], 7, was 
isolated from a solution of Ru-PPh3 in CHCl3, and X-ray identified. The antiproliferative activity of 1-
6 and Ru-PPh3, Ru-PPh3-O and [RuCl2(η
6-p-cymene)(κP-PTA)] (RAPTA-C) was assessed towards 
the triple-negative breast cancer cell line MDA-MB-231, the ovarian carcinoma cell line A2780 and 
human skin fibroblasts (HSF). Complexes 1, 2, 5 and 6 displayed IC50 values significantly lower than 
that of cisplatin, with 2 providing a more potent cytotoxic effect on MDA-MB-231 and A2780 cancer 
cells compared to the noncancerous cell line (HSF). The stability of all complexes in DMSO/water 
solution was elucidated by NMR and conductivity measurements, and in particular 35Cl NMR 
spectroscopy was helpful to check the possible chloride dissociation. The stability studies suggest that 
the cytotoxic activity in vitro of the compounds is mainly ascribable to Ru(II) species still bound to the 
phosphorus ligand. 
 
Keywords: metal-based drugs, ruthenium arene complexes, RAPTA complexes, triphenylphosphine 
ligands, breast cancer. 
 
 
3 
 
 
 
Introduction 
Cancer represents the first cause of death in economically developed countries, and the second in 
developing countries.1 A huge effort of scientific research is aimed to obtain new effective and 
selective metal drugs in view of overcoming the severe toxicity and acquired resistance issues 
associated with the use of platinum chemotherapics, which are currently used in clinical treatments.2 
Ruthenium compounds have been intensively investigated in this setting,3 and especially Ru(II) arene 
complexes have aroused a great interest.4 In particular, [RuCl2(η
6-p-cymene)(κP-PTA)] (RAPTA 
complexes),5 containing the amphiphilic phosphorus ligand 1,3,5-triaza-7-
phosphatricyclo[3.3.1.1]decane (PTA), and [RuCl(η6-arene)(κ2N-NH2CH2CH2NH2)][PF6],
6 containing 
a bidentate ethylene-1,2-diamine ligand, have emerged as promising anticancer agents and are pointing 
to clinical trials (Figure 1).7 With specific reference to RAPTA complexes, these display excellent 
antimetastatic and antiangiogenic behaviour in vivo and are able to reduce the growth of certain 
primary tumours.8 These features have stimulated the search for the anticancer potential of many other 
similar compounds, and RAPTA-analogues bearing various alkyl/aryl-phosphine ligands in the place of 
PTA have been screened for their activity.9 Noteworthy results have been achieved by Dyson and co-
workers with perfluoro-substituted trialkylphosphines, supplying thermotropic behaviour to the 
respective complexes,10 and carbohydrate-modified 3,5,6-bicyclophosphites, the resulting complexes 
showing a certain degree of selectivity against several cancer cells compared to non tumorigenic cell 
line.11  
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Figure 1. Ruthenium(II) arene anticancer complexes. 
 
On the other hand, the introduction of triphenylphosphine as a ligand, being considerably more 
hydrophobic than PTA, usually leads to higher levels of cytotoxicity in vitro, although at the expense 
of selectivity in some cases.12 For instance, [RuCl(η6-p-cymene)(py*)(PPh3)]
+, containing a substituted 
pyridine ligand (py*), exhibited activity against human leukemia tumour cell line comparable to that 
obtained with cisplatin.13 Moreover, Hartinger and co-workers recently reported that the incorporation 
of PPh3 (or PTA) in Ru(II) arene complexes containing a bidentate oxygen co-ligand (3-hydroxy-4-
pyridone or 3-hydroxy-4-pyrone) determined a dramatic increase of the cytotoxic activity on different 
cell lines,14 and a similar outcome was observed for [Ru(η6-benzene)(κN-letrozole)(PPh3)][BF4] vs. 
[Ru(η6-benzene)(κN-letrozole)2][BF4].
15 It has been demonstrated that the presence of a 
triphenylphosphine ligand is important also to facilitate the binding of the Ru complex to DNA and 
then distort its secondary and tertiary structure.13 
The investigation on Ru(II) arene compounds bearing substituted triphenylphosphine ligands has been 
limitedly developed. More precisely, Ph2P(4-C6H4CO2H) and Ph2P(4-C6H4OH) have been used to 
incorporate a variety of bioactive carboxylic acids within the Ru(II) para-cymene scaffold, through 
esterification reactions.16 The resulting [RuCl2(η
6-p-cymene)(κP-Ph2PAr
BIO)] complexes display 
variable activity towards A2780 and A2780cisR cancer cell lines, the degree of activity being 
significantly influenced by the nature of the bioactive fragment. 
Herein, we present the synthesis and the full characterization of six new Ru(II)-p-cymene complexes 
with differently mono-substituted triphenylphosphine or phenoxydiphenylphosphine ligands, including 
a dichloroacetic acid functionalized triphenylphosphine, a silyl ether substituted triphenylphosphine 
and a unprecedented silyl phenoxydiphenylphosphine. Dichloroacetic acid is a commercially available 
inhibitor of pyruvate dehydrogenase kinase, able to enhance cellular apoptosis.17 The incorporation of 
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dichloroacetic acid in platinum based drugs was reported to provide several favourable effects,18 and 
especially the Pt(IV) compound called "mitaplatin" displayed excellent characteristics of cytotoxicity 
and selectivity.19 To the best of our knowledge, dichloroacetic acid has not been tethered to ruthenium 
complexes for medicinal applications hitherto. Silicon-containing phosphine ligands have been 
considered in the present work in view of the peculiar properties that organosilicon compounds may 
supply to pharmaceuticals.20 
On account of the fact that platinum drugs are still the only viable options for the treatment of triple 
negative breast cancers and ovarian carcinomas, the new complexes have been assessed for their in 
vitro antiproliferative activity towards MDA-MB-231 (triple negative breast cancer) and A2780 
(ovarian carcinoma) cancer cell lines, and human skin fibroblasts (HSF) as non-transformed primary 
cell line. 
 
Results and discussion 
1. Synthesis and characterization of compounds.  
The reactions of the dinuclear compound [RuCl2(η
6-p-cymene)]2 with Ph2P(4-C6H4OSiMe2
tBu), 
Ph2P(4-C6H4Br), Ph2P(OPh) and Ph2P(O(2-C6H4SiMe2
tBu)), respectively, were conducted in 
chlorinated solvents at ambient temperature or above, and afforded the novel complexes 1-2 and 4-5, in 
good to excellent yields (Scheme 1b). The phosphine Ph2P(4-C6H4OSiMe2
tBu) is an intermediate 
product along the convenient synthesis of Ph2P(4-C6H4OH), the tert-butyl dimethyl silyl moiety being 
a protecting group.16a,21 Ph2P(O(2-C6H4SiMe2
tBu)) is a unprecedented compound, and was synthesized 
in 86% yield from the aryl-silylether 2-C6H4Br(OSiMe2
tBu) and n-BuLi/Ph2PCl via [1,3] retro-Brook 
rearrangement (Scheme 1d).22 
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Complex 3 was obtained in 83% yield by direct esterification of [RuCl2(η
6-p-cymene){κP-Ph2P(4-
C6H4OH)}] with dichloroacetic acid (a bioactive molecule, vide infra) through EDCI/DMAP protocol 
(Scheme 1a). This procedure, negating the necessity of protecting strategies towards the labile Ru-Cl 
bonds, is convenient on account of the fact it does not require the manipulation of non coordinated, air 
sensitive Ph2P(4-C6H4OH).
16a Complex 6, differing from 5 in that two chloride ligands are replaced 
with an oxalate, was straightforwardly prepared from [Ru(C2O4)(η
6-p-cymene)(H2O)] and Ph2P(O(2-
C6H4SiMe2
tBu)) (Scheme 1c).  
 
Scheme 1. Synthetic routes to ruthenium triphenylphosphine complexes (a-c) and Ph2P(O(2-C6H4SiMe2
t
Bu)) 
ligand (d). Yields are given in parentheses. 
 
All the complexes 1-6 and the ligand Ph2P(O(2-C6H4SiMe2
tBu)) were characterized by analytical 
methods, IR and NMR spectroscopy (see Table 1S provided as Supporting Information). In the IR 
spectrum of 3 (solid state), the ester group manifests itself with a broad band around 1770 cm−1, while 
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the carbonyl functions of 6 have been detected at 1666-1697 cm−1. In 4-5 and Ph2P(O(2-
C6H4SiMe2
tBu)), a strong absorption in the range 870-892 cm−1 has been attributed to the stretching 
vibration of the P-O moiety. The dichloroacetate group in 3 is featured also by the 13C NMR 
resonances occurring at 162.5 (C=O) and 64.2 (CHCl2) ppm. The 
31P{1H} NMR spectra of 1-3 display 
a typical singlet at ca. 24 ppm; the 31P NMR resonance related to the aryloxy-diphenylphosphine 
compounds 4, 5 and Ph2P(O(2-C6H4SiMe2
tBu)), in CDCl3 solution, falls at significantly lower fields. 
The phosphorus nucleus of Ph2P(O(2-C6H4SiMe2
tBu)) resonates at 108.3 ppm in the uncoordinated 
molecule, and at 120.3 ppm in 5. The 29Si NMR spectra of 5 and Ph2P(O(2-C6H4SiMe2
tBu)), 
comprising a carbon-bound silicon atom, consist of a singlet at approximately 3 ppm; on the other 
hand, the resonance related to the oxygen-bound silicon nucleus falls at 21.7 ppm in 1. 
Crystals suitable to X-ray analysis were collected for 3, 4, 5 and 6; views of the ORTEP molecular 
structures are shown in Figures 2-5, while relevant bonding parameters are provided as SI (Tables 12S-
15S). Compounds 3-6 comprise the expected three-leg piano-stool geometry typical of other Ru(II)-
arene compounds,23 and the bonding parameters around the Ru(II) centres are similar to those reported 
for related [RuCl2(p-cymene)(phosphine)] and [Ru(C2O4)(p-cymene)(phosphine)] structures.
24 
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Figure 2. Molecular structure of [RuCl2(η
6
-p-cymene){κP-Ph2P(4-C6H4OCOCHCl2)}], 3. Displacement ellipsoids 
are at the 30% probability level. H-atoms have been omitted for clarity. 
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Figure 3. Molecular structure of [RuCl2(η
6
-p-cymene){κP-Ph2P(OPh)}], 4. Displacement ellipsoids are at the 30% 
probability level. H-atoms have been omitted for clarity. 
 
 
Figure 4. Molecular structure of [RuCl2(η
6
-p-cymene){κP-Ph2PO(2-C6H4(SiMe2
t
Bu))}], 5. Displacement ellipsoids 
are at the 30% probability level. H-atoms have been omitted for clarity. 
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Figure 5. Molecular structure of [Ru(C2O4)(η
6
-p-cymene){κP-Ph2PO(2-C6H4(SiMe2
t
Bu))}], 6. Displacement 
ellipsoids are at the 50% probability level. H-atoms have been omitted for clarity. 
 
Complexes 1-6 are air stable and well soluble in chlorinated solvents, but not indefinitely stable in 
chloroform upon air contact. According to IR/NMR experiments (see Supporting Information for 
details), 1 and 6 in chloroform completely degraded after two weeks, the red/yellow solutions 
progressively turning to green and affording a complicated mixture of species including p-cymene. A 
similar behaviour was found for [RuCl2(η
6-p-cymene)(κP-PPh3)] (Ru-PPh3); in this case, some green 
crystals of the dinuclear, mixed valence RuII-RuIII compound [Ru(µ-Cl)3(η
6-p-cymene)RuCl2(κP-
PPh3)], 7,
25 were isolated from the reaction solution, and then identified by X-ray diffraction (Scheme 
2). Complexes belonging to the family [Ru(µ-Cl)3(η
6-p-cymene)RuCl2(κP-PR3)] (R = Ph, Cy, n-Bu) 
were previously reported as prepared from [RuCl2(η
6-p-cymene)]2 and the appropriate phosphine, upon 
ethylene addition.26, 
Instability of Ru(η6-arene) derivatives in chlorinated solvents is documented in the literature27 and 
possibly associated to the decomposition of the solvent into HCl and carbon radicals.28 Interestingly, 
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Ru(II) complexes have been used as catalysts for the photodegradation of chloroform and other 
chlorinated compounds.28b,29 
 
Scheme 2. Degradation route of Ru(II)-arene triphenylphosphine complex in chloroform solution upon air 
contact. 
 
Although Ru(II) arene complexes with phosphine ligands may undergo, in chloroform in contact with 
air, degradation routes including Ru(II) to Ru(III) oxidation, the same compounds are not expected to 
be engaged in redox processes in the course of the in vitro cytotoxicity analyses (vide infra). In fact, 
former electrochemical studies on a variety of Ru(II) arene compounds did not evidence redox activity 
within a biologically relevant range of potentials.16e,30  
 
2. In vitro cytotoxicity studies. 
The ability of the newly prepared compounds 1-6 to inhibit cell growth was evaluated against the 
triple-negative breast cancer cell line MDA-MB-231 (Figure 6A and Table 1), and the human ovarian 
carcinoma cell line A2780 (Figure 6B and Table 1). The analyses were extended to [RuCl2(η
6-p-
cymene)(κP-PPh3)] (Ru-PPh3), [Ru(C2O4)(η
6-p-cymene)(κP-PPh3)] (Ru-PPh3-O) and [RuCl2(η
6-p-
cymene)(κP-PTA)] (RAPTA-C), as reference compounds. Cells were incubated with increasing 
concentration of compounds dissolved in DMSO. 
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Figure 6. Cytotoxic activity of 1-6, Ru-PPh3, Ru-PPh3-O and RAPTA-C towards: A) MDA-MB-231 cell line; B) 
A2780 cell line. Each bar represents the mean ± SD of three independent experiments. Inhibitors versus control: 
*P <0.05; **P <0.01; ***P <0.001. 
 
Comparable cytotoxic effects were ascertained for the respective compounds on the two tumoral cell 
lines. In particular, 1, 2, 5 and 6 showed a considerable cytotoxic activity, although a tendency to 
stimulate the growth of MDA-MB-231 cells was observed for 2 and 5 at low concentrations (see Figure 
6). The IC50 values are substantially lower than the values obtained with cisplatin on the same cell lines 
under the same experimental conditions. Otherwise, 3, 4, Ru-PPh3, Ru-PPh3-O and RAPTA-C did not 
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reduce the cell viability by more than 50% at the maximal tested concentration (50 µM). It should be 
noted that RAPTA-C was previously found to be non cytotoxic against a panel of cell lines.5 
These results clearly indicate that the mono-substitution of one phenyl ring, in PPh3 or PPh2(OPh), can 
lead to a significant increase in the cytotoxicity of the resulting complexes (compare Ru-PPh3 with 1-
2, and 4 with 5-6). The relatively high activity exhibited by 1, 5 and 6 could be somehow related to the 
presence of the tert-butyl dimethyl silyl substituent. As a matter of fact, tert-butyl dimethyl silyl, 
tethered to tetrahydropyran rings, was previously indicated as an enhancer of cytotoxicity against HL60 
human leukemia cells and MCF7 breast cancer cells in vitro, due to its lipophilicity favouring the 
cellular uptake of the drug.31 
It is possible that the drop of activity observed on moving from 1-2 to 3 is related to some unexpected 
effect associated with dichloroacetic acid,19 which may be released from 3 inside the cells by means of 
intracellular esterases.32 Compounds homologous to 3, [RuCl2(η
6-p-cymene)(κP-Ph2PAr
BIO)], 
derivatized with bioactive carboxylic acids different from CHCl2CO2H, displayed variable cytotoxic 
activity towards A2780 and A2780cisR cancer cell lines (see Introduction) and, in one case 
(derivatization with Indomethacin), not appreciable activity.16a  
We further explored the possible effect of 3 on cell viability by analysing the cell cycle progression 
after 24h incubation of A2780 cells (Table 2). We detected a lowering in the percentage of cells in S 
and G2/M phase compared to untreated cells, suggesting a possible interference of 3 with the 
progression from G1 to S phase. No sub G0 cells were observed, in agreement with the relatively low 
cytotoxicity exhibited by the complex and the absence of induction of apoptosis, under the employed 
experimental conditions. 
In order to assess the possible selectivity of the more active compounds (1, 2, 5 and 6) towards cancer 
cells rather than non transformed cells, we extended the analysis of the antiproliferative activity to 
human skin fibroblasts (HSF). Complexes 1, 5 and 6 are not endowed with cancer cell selectivity, i.e. 
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they are cytotoxic also to the HSF. Conversely, a moderate selectivity has been observed in the case of 
the Br-functionalized complex 2 [selectivity indexes are 2.3 (HSF/MDA-MB-231) and 4.6 
(HSF/A2780)]: according to this result, the inclusion of Ph2P(4-C6H4Br) in ruthenium arene 
compounds might represent a privileged choice with respect to the use of PPh3 (see Introduction). 
 
Compound MDA-MB-231 A2780 HSF 
1 9.2 ± 1.1 3.6 ± 0.6 7.2 ± 1.0 
2 13.9 ± 1.2 7.0 ± 1.6 31.9 ± 1.1 
3 >50 >50 N/T 
4 >50 >50 N/T 
5 29.1 ± 1.4 9.4 ± 2.6 7.8 ± 1.1 
6 14.4 ± 1.2 7.6 ± 1.2 12.5 ± 1.0 
Ru-PPh3 >50 >50 N/T 
Ru-PPh3-O >50 >50 N/T 
RAPTA-C >50 >50 N/T 
Cisplatin 59.4 
33
 31.5 N/T 
Table 1. IC50 values (µM) determined for 1-6, Ru-PPh3, Ru-PPh3-O, RAPTA-C and cisplatin, on human breast 
(MDA-MB-231) cancer cells and human skin fibroblasts (HSF) cells at 48 h. Values are given as the mean ± SD. 
N/T not tested. 
 
Compound G0/G1 phase (%) S phase (%) G2/M phase (%) 
Control 60.5 20.1 19.4 
3 78.9 4.5 16.7 
T-test p<0.001 p<0.001 P=0.04 
 
Table 2. Effect of complex 3 on cell cycle progression of A2780 cell line. Cells were incubated for 24h either in 
the presence or in the absence of 3 (50µM). At the end of this incubation period, the cell cycle analysis was 
performed. 
 
3. Chloride/solvent exchange on model compounds and stability of 1-6 in aqueous solution. 
We performed NMR experiments (1H, 31P, 35Cl) and conductivity measurements to assess the stability 
of 1-6 and model compounds under pseudo-physiological conditions (see also Experimental Section 
and Supporting Information). In particular, 35Cl NMR spectroscopy revealed to be a helpful tool to 
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detect the solvolysis of the Ru-Cl bonds. 35Cl is a quadrupolar nucleus, thus covalently bound chlorines 
give raise to broad resonances in the 35Cl NMR spectrum and are difficult to observe in a reasonable 
time. Otherwise, the chloride anion can be readily recognized: for instance, NaCl (D2O solution) and 
[Et3NH]Cl (CD3OD solution) display sharp 
35Cl resonances at 0.0 ppm (reference) and −22.7 ppm, 
respectively (see Experimental). In agreement with literature reports,34 we clearly detected fast 
chloride/water exchange on RAPTA-C in D2O solution by 
35Cl NMR (Scheme 3a). On the other hand, 
35Cl NMR indicated no Cl−/solvent exchange when RAPTA-C was dissolved in CD3OD, and even in 
CD3OD/D2O 9:1 and DMSO-d6/D2O 9:1 mixtures (Scheme 3b). Under these conditions, a single set of 
1H and 31P NMR resonances was observed, in accordance with the RAPTA-C structure. Conversely, 
when one equivalent of AgNO3 was added to the CD3OD/D2O 9:1 solution (Cl
− abstraction, Scheme 
3c), the 1H NMR pattern was in agreement with the structure [RuCl(η6-p-cymene)(Solv)(PTA)]+ 
(stereogenic Ru-centre), and a marked increase in molar conductivity was measured too (from 35 to 81 
S·cm2·mol-1). 
 
 
Scheme 3. Behaviour of RAPTA-C in aqueous solutions; presence/absence of Cl− ascertained by 
35
Cl NMR 
spectroscopy. 
 
Due to limited solubility in water, stability studies on [RuCl2(η
6-p-cymene)]2, Ru-PPh3, Ru-PPh3-O 
and 1-6 were carried out in DMSO/water 9:1 solutions. An overview of the different NMR identified 
species after 72 h is shown in Scheme 4, while the fraction of the starting material detected after 0, 24 
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and 48 h is given in Table 3. Analogously to what found for RAPTA-C in DMSO-d6/D2O 9:1, 
35Cl 
NMR experiments conducted on freshly prepared solutions suggested to rule out fast chloride 
dissociation from 1-3, Ru-PPh3 and [RuCl2(η
6-p-cymene)]2.
35 Coherently, the respective 1H and 31P 
spectra, displaying a single set of resonances for the p-cymene ligand (Cs symmetry), did not modify 
upon addition of 0.15 M NaCl. Moreover, molar conductivity of the DMSO:water 9:1 solutions was 
significantly lower (≈ 20-25 S·cm2·mol–1) than expected for a 1:1 electrolyte in this solvent (≈ 50 
S·cm2·mol–1, see SI). The set of signals (1H, 31P) belonging to the starting Ru-dichlorido complex 
persisted throughout the stability experiments (37°C, 72 h), and the only other set of observed Ru-arene 
1H signals was due to the formation of [RuCl2(η
6-p-cymene)(DMSO)] (see Scheme 4).   
The dimeric compound [RuCl2(η
6-p-cymene)]2 was cleanly cleaved into [RuCl2(η
6-p-
cymene)(DMSO)], S1, in DMSO/water 9:1 as well as in pure DMSO.36 It should be mentioned that a 
sharp 35Cl signal was previously reported for [RuCl2(η
6-C6Et6)]2 in methanol solution at −50 °C, but 
not at ambient temperature. Such phenomenon was attributed to the existence of the equilibrium 
[RuCl2(η
6-C6Et6)]2  [Ru2Cl3(η
6-C6Et6)]Cl, shifting in favour of the ionic species at low temperature, 
rather than to a possible fast chloride/solvent exchange on the NMR timescale.27b 
Progressive phosphine/DMSO exchange was detected for 1-5 and Ru-PPh3 during 72 h. In 6 and Ru-
PPh3-O, lacking of chloride ligands but containing a bis-carboxylate group, the phosphine release was 
significantly inhibited; the solvato-species [Ru(C2O4)(η
6-p-cymene)(DMSO)], S2, was formed from 6 
in low amount only after 72 h.  
It seems reasonable that, in accordance with the behaviour of RAPTA-C (Scheme 3) and some water-
soluble [RuCl2(η
6-p-cymene)(PAr3)] complexes,
37 1-6 may undergo Cl−/solvent exchange more easily 
in diluted (micromolar) solutions with a higher relative content of water, as is the case of cell culture. 
This process is expected to afford cationic species, basically [RuCl(η6-p-cymene)(H2O)(PPh2R)]
+, 
whereby the solvolysis of the phosphine ligand should be inhibited with respect to what observed on 
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the parent neutral derivatives, [RuCl2(η
6-p-cymene)(PPh2R)], in DMSO:D2O 9:1 (Scheme 4). In other 
terms, the degree of phosphine dissociation recognized for the complexes in DMSO/water is probably 
overestimated respect to the real situation of the in vitro trials.  
The disruptive effect of DMSO is likely to be responsible also for the observed, partial release of the p-
cymene ligand from 1-6, Ru-PPh3 and Ru-PPh3-O (Scheme 4).
38 Indeed, arene dissociation from 
Ru(II) complexes in water is generally not observed39 unless under UV irradiation.40  
Accounting all of these considerations, the cytotoxic activity of 1-6 is plausibly related for the most 
part to non dissociated ruthenium-phosphine species. 
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Scheme 4. Compounds detected in DMSO-d6/D2O solutions of 1-6, [RuCl2(η
6
-p-cymene)]2, Ru-PPh3, Ru-PPh3-
O and RAPTA-C maintained at 37 °C for 72 h. 
  
 
% (
1
H NMR vs. internal standard) 
Compound 
t = 0 t = 23.5 h t = 48 h 
1 97 70 24 
2 97 67 45 
3 95 56 37 
4 94 25 14 
5 96 33 6 
6 100 75 56 
Ru-PPh3 98 77 56 
Ru-PPh3-O 99 77 74 
RAPTA-C 100 90 
[a]
 63 
[b]
 
 
Table 3. Fraction of complexes 1-6, Ru-PPh3, Ru-PPh3-O and RAPTA-C in DMSO-d6/D2O at 37 °C after 24 h 
and 48 h; % values are based on 
1
H NMR spectroscopy (dimethyl sulfone as internal standard). [a] t = 16.5 h. [b] 
t = 40.5 h. 
 
 
Conclusions 
Since a variety of ruthenium(II) arene complexes containing a phosphine ligand have aroused interest 
for their possible anticancer activity, we have prepared and characterized a series of new Ru(II) arene 
complexes containing a triphenylphosphine or phenoxydiphenylphosphine ligand, variably mono-
substituted at one phenyl ring. In general, the substitution leads to an increase of the cytotoxic activity 
of the complexes (MDA-MB-231 and A2780 cancer cell lines), some of them displaying IC50 values 
much lower than those related to cisplatin. A moderate level of selectivity towards cancer cells respect 
to non tumorous cells has been observed with (4-bromophenyl)diphenylphosphine, whose use might 
become convenient when the synthetic design of antitumoral ruthenium arene compounds includes the 
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incorporation of a triphenylphosphine moiety. According to stability studies carried out in aqueous 
solutions, we presume that the in vitro cytotoxic activity of the compounds is largely ascribable to 
phosphine-bound Ru(II) species. Although the cross combination with other techniques seems needed 
for conclusive information, 35Cl NMR spectroscopy is helpful to study the possible solvolysis of Ru-Cl 
bonds, which represents a largely accepted mechanism for drug activation. 
 
Experimental Section. 
General experimental details. RuCl3·3H2O (99.9%) was purchased from Strem, while all the other 
reactants were obtained from Alfa Aesar, Sigma Aldrich or TCI Europe, and were of the highest purity 
available. The following reagents were stored under nitrogen or argon as received: 2-bromophenol 
(under protection from the light), triethylamine, tert-butyldimethylsilyl chloride (TBDMSCl), butyl 
lithium (2.5 M solution in hexanes, 4 °C), chlorodiphenylphosphine, phenoxydiphenylphosphine (4 
°C), PCl5, oxalyl chloride (4 °C), ethyl(diisopropylamino)carboxydiimide hydrochloride (EDCI·HCl, 
−20 °C). Dichloroacetic acid was distilled under reduced pressure, dried under vacuum over P2O5 and 
stored under nitrogen. Ph2P(4-C6H4Br),
41 [Ru(C2O4)(η
6-p-cymene)(H2O)],
24c [RuCl2(η
6-p-cymene)(κP-
PPh3)],
42
 and [Ru(C2O4)(η
6-p-cymene)(κP-PPh3)]
43
 were prepared according to modified literature 
procedures (see Supporting Information). [RuCl2(η
6-p-cymene)]2,
44 [RuCl2(η
6-p-cymene)(PTA)] 
(RAPTA-C),45 Ph2P(4-C6H4OSiMe2
tBu)16a and [RuCl2(η
6-p-cymene)(Ph2P(4-C6H4OH))]
16a were 
prepared according to the literature. All reactions, except the preparation of [Ru(C2O4)(η
6-p-
cymene)(H2O)], were carried out under a nitrogen atmosphere using standard Schlenk techniques and 
solvents distilled from appropriate drying agents. Once isolated, o-C6H4Br(OSiMe2
tBu), Ph2PO(2-
C6H4(SiMe2
tBu)), o-C6H4(OH)(SiMe2
tBu) (under protection from the light), Ph2P(4-C6H4OSiMe2
tBu) 
and Ph2P(4-C6H4Br) were stored under nitrogen, all the other products being air stable. Compound 
[Ru(C2O4)(η
6-p-cymene)(H2O)] was either used some days after its preparation or stored under 
 
 
21 
 
 
nitrogen for longer periods. Silica gel (Merck, 70-230 mesh) was dried at 150 °C overnight and stored 
under nitrogen. NMR spectra were recorded at 298 K on a Bruker Avance II DRX400 instrument 
equipped with a BBFO broadband probe. Chemical shifts (expressed in parts per million) are 
referenced to the residual solvent peaks46 (1H, 13C) or to external standard (31P to 85% H3PO4; 
29Si to 
TMS, 35Cl to 1 M NaCl in D2O). Spectra were assigned with the assistance of 
1H{31P}, DEPT-135 
spectra and 1H-1H (COSY), 1H-13C (gs-HSQC and gs-HMBC) correlation experiments.47 Infrared 
spectra of solid samples were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer, equipped 
with a UATR sampling accessory. Infrared spectra of CH2Cl2 solutions were recorded on a Perkin 
Elmer Spectrum 100 FT-IR spectrometer with a CaF2 liquid transmission cell. UV-Vis spectra were 
recorded on a Ultraspec 2100 Pro spectrophotometer with 0.1 cm quartz cuvettes. IR and UV-Vis 
spectra were processed with Spectragryph software.48 Carbon, hydrogen and nitrogen analysis was 
performed on a Carlo Erba mod. 1106 instrument. Melting/decomposition temperatures were 
determined on a STMP3 Stuart scientific instrument with a capillary apparatus. Conductivity 
measurements49 were carried out at 21°C using an XS COND 8 instrument (cell constant = 1.0 cm−1).  
 
Synthesis of new compounds. 
A. Synthesis of [RuCl2(η
6
-p-cymene){κP-Ph2P(4-C6H4OSiMe2
t
Bu)}], 1. 
Chart 1. Structure of 1 (numbering refers to carbon atoms). 
 
 
In a 25 mL Schlenk tube, [RuCl2(η
6-p-cymene)]2 (254 mg, 0.415 mmol) and Ph2P(4-C6H4OSiMe2
tBu) 
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(389 mg, 0.991 mmol) were dissolved in CH2Cl2 (10 mL). The resulting deep red solution was stirred 
at ambient temperature for 7.5 hours and the formation of a ruthenium-coordinated phosphine 
compound was assessed by TLC, 29Si and 31P NMR. Therefore volatiles were removed under vacuum 
and the residue was suspended in pentane (20 mL). The suspension was cooled to 0 °C and filtered; the 
resulting orange-brown solid was washed with a small volume of cold pentane and dried under vacuum 
(45 °C). Yield: 469 mg, 81%. The title compound is soluble in DMSO, EtOH, CH2Cl2 and Et2O, less 
soluble in pentane/petroleum ether and insoluble in H2O. Anal. calcd. for C34H43Cl2OPRuSi: C, 58.44; 
H, 6.20; Cl, 10.15. Found: C, 58.16; H, 6.25; Cl, 10.02. IR (solid state): ῦ/cm-1 = 3055w, 2957w, 
2929w, 2896w, 2885w, 2857w, 1591m, 1497s, 1482m-sh, 1471m, 1435m, 1401w, 1388w, 1361w, 
1257s-br, 1176s (νO-Ar), 1093s, 1057w, 1029w, 1005w, 907s, 838s, 824s-sh, 806s, 781s, 744m, 719w, 
693s, 673m-sh. 1H NMR (CDCl3): δ/ppm = 7.83–7.76 (m, 4H, C9-H), 7.70 (pseudo-t, 
3
JHH = 
3
JHP = 9 
Hz, 2H, C13-H), 7.40–7.32 (m, 6H, C10-H + C11-H), 6.82 (d, 3JHH = 7.3 Hz, 2H, C14-H), 5.19 (d, 
3
JHH 
= 5.8 Hz, 2H, C4-H), 4.98 (d, 3JHH = 5.5 Hz, 2H, C3-H), 2.87 (hept, 
3
JHH = 6.1 Hz, 1H, C6-H), 1.86 (s, 
3H, C1-H), 1.10 (d, 3JHH = 6.9 Hz, 6H, C7-H), 0.97 (s, 9H, C18-H), 0.20 (s, 6H, C16-H). 
13C{1H} 
NMR (CDCl3): δ/ppm = 157.7 (C15), 136.4 (d, 
2JCP = 11 Hz, C13), 134.5 (d, 
1JCP = 46 Hz, C8), 134.3 
(d, 2JCP = 9 Hz, C9), 130.2 (d, 
4
JCP = 2 Hz, C11), 128.0 (d, 
3
JCP = 10 Hz, C10), 125.0 (d, 
1
JCP = 50 Hz, 
C12), 119.7 (d, 3JCP = 11 Hz, C14), 111.1 (d, 
2
JCP = 3 Hz, C5), 96.0 (C2), 89.1 (d, 
2
JCP = 3 Hz, C3), 
87.3 (d, 2JCP = 6 Hz, C4), 30.4 (C6), 25.7 (C17), 22.0 (C7), 18.3 (C18), 17.9 (C1), -4.5 (C16). 
31P{1H} 
NMR (CDCl3): δ/ppm = 23.2. 
29Si{1H} NMR (CDCl3): δ/ppm = 21.7. 
 
B. Synthesis of [RuCl2(η
6
-p-cymene){κP-Ph2P(4-C6H4Br)}], 2. 
Chart 2. Structure of 2 (numbering refers to carbon atoms). 
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In a 25 mL Schlenk tube, [RuCl2(η
6-p-cymene)]2 (65 mg, 0.106 mmol) and Ph2P(4-C6H4Br) (79 mg, 
0.232 mmol) were dissolved in CHCl3 (12 mL). The resulting red solution was heated at reflux for 15 
hours and the progress of reaction was checked by TLC. The reaction mixture was cooled to ambient 
temperature, volatiles were removed under vacuum and the residue was dissolved in a small volume of 
CH2Cl2. Addition of hexane under vigorous stirring caused the precipitation of the title compound as a 
red solid. The suspension was filtered; the solid was washed with hexane and then with a small volume 
of hexane/Et2O mixture (1:1 v/v ratio), and finally dried under vacuum (40 °C). Yield: 125 mg, 91%. 2 
was obtained in admixture with minor products when the reaction was performed at ambient 
temperature. The title compound is soluble in DMSO, acetone and chlorinated solvents, less soluble in 
MeOH, poorly soluble in Et2O and insoluble in H2O and hexane. Anal. calcd. for C28H28BrCl2PRu: C, 
51.95; H, 4.36; Cl, 10.95. Found: C, 52.06; H, 4.23; Cl, 10.84. IR (solid state): ῦ/cm-1 = 3049w, 2960w, 
2925w, 2870w, 1572w, 1556w, 1480m, 1468m-sh, 1434m, 1384m, 1325w, 1277w, 1189m, 1161w, 
1117w, 1094m, 1070m, 1058m-sh, 1028w, 1009m, 951w, 926w, 896w, 869w, 811m, 799m-sh, 752m, 
725s, 698s. 1H NMR (CDCl3): δ/ppm = 7.83–7.76 (m, 4H, C9-H), 7.70 (pseudo-t, 
3
JHH = 
3
JHP = 8.9 Hz, 
2H, C13-H), 7.47–7.34 (m, 8H, C10-H + C11-H + C14-H), 5.21 (d, 3JHH = 4.9 Hz, 2H, C3-H/C4-H), 
4.99 (d, 3JHH = 4.4 Hz, 2H, C3-H/C4-H), 2.84 (hept, 
3
JHH = 6.5 Hz, 1H, C6-H), 1.85 (s, 3H, C1-H), 
1.10 (d, 3JHH = 6.7 Hz, 6H, C7-H). 
13C{1H} NMR (CDCl3): δ/ppm = 136.3 (d, 
2
JCP = 10 Hz, C13), 
134.2 (d, 2JCP = 10 Hz, C9), 133.8 (d, 
1
JCP = 45 Hz, C8), 132.3 (d, 
1
JCP = 46 Hz, C12), 131.0 (d, 
3
JCP = 
10 Hz, C14), 130.6 (d, 4JCP = 2 Hz, C11), 128.3 (d, 
3JCP = 10 Hz, C10), 125.3 (d, 
4JCP = 3 Hz, C15), 
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111.5 (d, 2JCP = 3 Hz, C5), 96.3 (C2), 89.1 (d, 
2
JCP = 3 Hz, C3/C4), 87.4 (d, 
2
JCP = 5 Hz, C3/C4), 30.4 
(C6), 22.0 (C7), 17.9 (C1). 31P{1H} NMR (CDCl3): δ/ppm = 24.4. 
 
C. Synthesis of [RuCl2(η
6
-p-cymene){κP-Ph2P(4-C6H4OCOCHCl2)}], 3. 
Chart 3. Structure of 3 (numbering refers to carbon atoms). 
 
 
In a 25 mL Schlenk tube, CH2Cl2 (6 mL), Cl2CHCO2H (30 µL, 0.36 mmol), [RuCl2(η
6-p-cymene){κP-
Ph2P(4-C6H4OH)}] (75 mg, 0.13 mmol), EDCI·HCl (97 mg, 0.51 mmol) and DMAP (6 mg, 0.05 
mmol) were introduced in the order given. The resulting red solution was stirred at ambient 
temperature and aliquots of the solution were taken for 1H and 31P NMR analysis. After 2.5 hours, 
volatiles were removed under vacuum. Shortly afterwards, the residue was dissolved in a small volume 
of CH2Cl2, the solution was diluted with EtOAc (10 mL) and then extracted with water (3x20mL). 
Volatiles were removed under vacuum from the organic phase and the residue was dissolved in a small 
volume of DCM/Et2O (1:1 v/v). Hexane addition under intense stirring caused the precipitation of the 
title compound as a red-brown powder. The suspension was filtered and the solid was washed with 
hexane and dried under vacuum (40 °C). Yield: 75 mg, 83%. Note: it is important for the workup to be 
performed immediately after the end of the reaction. The title compound is soluble in chlorinated 
solvents and DMSO, less soluble in Et2O, insoluble in hexane and water. X-ray quality crystals of 
3acetone were obtained from an acetone solution of 3 layered with heptane and settled aside at -20 °C. 
Anal. calcd. for C30H29Cl4O2PRu: C, 51.81; H, 4.20; Cl, 20.39. Found: C, 51.67; H, 4.28; Cl, 20.26. IR 
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(solid state): ῦ/cm-1 = 3055w, 2962w, 2929w-sh, 2870w, 1785m-sh and 1768m (νC=O), 1587w, 1493m, 
1483m, 1471w, 1435m, 1396w, 1386w, 1289m, 1234m, 1205m, 1168s (νO-Ar), 1139m, 1093m, 1057w, 
1028w, 1017m, 999w, 938w, 858m, 822m, 798m, 747m, 695s. 1H NMR (CDCl3): δ/ppm = 7.90 
(pseudo-t, 3JHH = 
3
JHP = 8.2 Hz, 2H, C13-H), 7.81 (pseudo-t, 
3
JHH = 
3
JHP = 8.2 Hz, 4H, C9-H), 7.46–
7.36 (m, 6H, C10-H + C11-H), 7.12 (d, 3JHH = 7.5 Hz, 2H, C14-H), 6.13 (s, 1H, C17-H), 5.20 (d, 
3
JHH 
= 4.2 Hz, 2H, C3-H/C4-H), 5.01 (d, 3JHH = 3.7 Hz, 2H, C3-H/C4-H), 2.81 (hept, 
3
JHH = 6.1 Hz, 1H, 
C6-H), 1.85 (s, 3H, C1-H), 1.09 (d, 3JHH = 6.1 Hz, 6H, C7-H). 
13C{1H} NMR (CDCl3): δ/ppm = 162.5 
(C16), 151.4 (d, 4JCP = 2 Hz, C15), 136.3 (d, 
2JCP = 10 Hz, C13), 134.2 (d, 
2JCP = 10 Hz, C9), 133.8 (d, 
1
JCP = 45 Hz, C8), 132.0 (d, 
1
JCP = 47 Hz, C12), 130.6 (d, 
4
JCP = 1 Hz, C11), 128.3 (d, 
3
JCP = 10 Hz, 
C10), 120.1 (d, 3JCP = 11 Hz, C14), 111.3 (C5), 96.2 (C2), 89.2 (d, 
2
JCP = 2 Hz, C3/C4), 87.3 (d, 
2
JCP = 
5 Hz, C3/C4), 64.2 (C17), 30.3 (C6), 21.9 (C7), 17.8 (C1). 31P{1H} NMR (CDCl3): δ/ppm = 24.0. 
Freshly-prepared solutions of 3 in CDCl3 and DMSO-d6 show broadening of NMR resonances, 
probably due to association phenomena. A regular 1H spectrum can be obtained after some hours at 
ambient temperature. 1H NMR (CD3OD): δ/ppm = 7.91 (pseudo-t, 
3JHH = 
3JHP = 9.1 Hz, 2H, C13-H), 
7.88–7.80 (m, 4H, C9-H), 7.52–7.36 (m, 6H, C10-H + C11-H), 7.19 (d, 3JHH = 7.4 Hz, 2H, C14-H), 
6.71 (s, 1H, C17-H), 5.32 (d, 3JHH = 5.5 Hz, 2H, C3-H/C4-H), 5.22 (d, 
3
JHH = 4.9 Hz, 2H, C3-H/C4-H), 
2.63 (hept, 3JHH = 7.1 Hz, 1H, C6-H), 1.88 (s, 3H, C1-H), 1.07 (d, 
3
JHH = 6.7 Hz, 6H, C7-H). 
31P{1H} 
NMR (CD3OD): δ/ppm = 24.0. 
Solutions containing Cl2CHCOCl, freshly prepared from dichloroacetic acid (see SI), reacted with 
[RuCl2(η
6-p-cymene)(Ph2P(4-C6H4OH))] and Et3N affording mixtures of products including 3. 
 
D. Synthesis of [RuCl2(η
6
-p-cymene)(κP-Ph2POPh)], 4. 
Chart 4. Structure of 4 (numbering refers to carbon atoms). 
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In a 25 mL Schlenk tube, [RuCl2(η
6-p-cymene)]2 (133 mg, 0.218 mmol) and Ph2P(OPh) (145 mg, 
0.521 mmol) were dissolved in CHCl3 (7 mL). The resulting red solution was stirred at ambient 
temperature for 15 hours and the progress of reaction was checked by TLC. Volatiles were removed 
under vacuum and the residue was suspended in petroleum ether (20 mL). The suspension was filtered 
and the resulting orange-red solid was washed with petroleum ether and dried under vacuum (40 °C). 
Yield: 251 mg, 98%. The title compound is soluble in DMSO and chlorinated solvents, less soluble in 
acetone and EtOH and insoluble in H2O and hydrocarbons. Crystals suitable for X-ray analysis were 
obtained from CH2Cl2 solutions of 4 layered with either Et2O or hexane, and settled aside at -20 °C. 
Anal. calcd. for C28H29Cl2OPRu: C, 57.54; H, 5.00; Cl, 12.13. Found: C, 57.46; H, 4.92; Cl, 12.21. IR 
(solid state): ῦ/cm-1 = 3055w, 2965w, 2874w, 1589m, 1491m, 1481m, 1435m, 1389w, 1374w, 1288w, 
1238w, 1208s (νO-Ar), 1185m, 1174m, 1158w, 1104m-sh, 1093m, 1075w, 1056w, 1028w, 998w, 956w, 
926w, 889s (νP-O), 859m, 826w, 798w, 764s, 750s, 727s, 708s, 697s, 689s. 
1H NMR (CDCl3): δ/ppm = 
8.04–8.00 (m, 4H, C9-H), 7.38–7.31 (m, 6H, C10-H and C11-H), 7.31–7.22 (m, 4H, C13-H + C14-H), 
7.04 (t, 3JHH = 7.0 Hz, 1H, C15-H), 5.26 (pseudo-q, 
3
JHH = 5.8 Hz, 4H, C3-H + C4-H), 2.54 (hept, 
3
JHH 
= 6.6 Hz, 1H, C6-H), 1.50 (s, 3H, C1-H), 0.85 (d, 3JHH = 6.8 Hz, 6H, C7-H). 
13C{1H} NMR (CDCl3): 
δ/ppm = 152.9 (d, 2JCP = 5 Hz, C12), 136.2 (d, 
1
JCP = 48 Hz, C8), 132.1 (d, 
2
JCP = 11 Hz, C9), 130.9 (d, 
4
JCP = 1 Hz, C11), 129.8 (C14), 128.0 (d, 
3
JCP = 10 Hz, C10), 123.7 (C15), 120.8 (d, 
3
JCP = 6 Hz, C13), 
110.5 (C5), 97.3 (C2), 91.4 (d, 2JCP = 4 Hz, C3/C4), 87.6 (d, 
2
JCP = 5.8 Hz, C3/C4), 30.1 (C6), 21.5 
(C7), 17.3 (C1). 31P{1H} NMR (CDCl3): δ/ppm = 113.7. 
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E. Synthesis and characterization of Ph2P(O(2-C6H4SiMe2
t
Bu)). 
Chart 5. Structures of 2-C6H4(Br)(OSiMe2
tBu) (left) and Ph2P(O(2-C6H4SiMe2
tBu)) (right) 
(numbering refers to carbon atoms). 
  
 
Step 1.50 In a 100-mL Schlenk tube, Et3N (1.8 mL, 13 mmol) and TBDMSCl (1.88 g, 12.5 mmol) were 
added to a solution of 2-bromophenol (1.0 mL, 9.3 mmol) in CH2Cl2 (15 mL). The pale yellow solution 
was stirred at ambient temperature for 4.5 hours under protection from the light and the progress of 
reaction was monitored by TLC. The resulting pale yellow suspension was extracted with H2O (3x20 
mL), then the volatiles were removed from the organic phase under vacuum (50 °C). The product 2-
C6H4(Br)(OSiMe2
tBu) was obtained as a pale yellow liquid. Yield: quantitative. 1H NMR (CDCl3): 
δ/ppm = 7.63 (dd, 3JHH = 7.9, 
4
JHH = 1.6 Hz, 1H, C8-H), 7.28 (td, 
3
JHH = 7.7, 
4
JHH = 1.6 Hz, 1H, C6-H), 
6.99 (dd, 3JHH = 8.1, 
4JHH = 1.5 Hz, 1H, C5-H), 6.92 (td, 
3JHH = 7.4, 
4JHH = 1.4 Hz, 1H, C7-H), 1.17 (s, 
9H, C1-H), 0.37 (s, 6H, C3-H). 13C{1H} NMR (CDCl3): δ/ppm = 152.6 (C4), 133.5 (C8), 128.3 (C6), 
122.4 (C7), 120.4 (C5), 115.5 (C9), 26.0 (C1), 18.6 (C2), -4.0 (C3). 
Step 2. In a 100 mL Schlenk tube, n-BuLi (3.8 mL of a 2.5 M solution in hexanes, 9.5 mmol) was 
slowly added (15') to a colourless solution of 2-C6H4(Br)(OSiMe2
tBu) (2.70 g, 9.4 mmol) in Et2O (20 
mL), at 0 °C under vigorous stirring. The resulting pale yellow solution was allowed to reach ambient 
temperature and stirred for additional 1.5 hours. Therefore Ph2PCl (1.75 mL, 9.5 mmol) was added 
dropwise to the solution along five minutes time at 0 °C, and precipitation of a colourless solid (LiCl) 
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occurred. The resulting suspension was allowed to reach ambient temperature and then stirred for 
additional 20 hours. The reaction mixture was concentrated under reduced pressure, loaded on top of a 
silica column (h = 4 cm, d = 3 cm) and eluted with hexane. The title compound was obtained as a 
colourless solid after solvent removal under vacuum (50 °C). Yield: 3.12 g, 86%. Anal. Calcd. for 
C24H29OPSi: C, 73.43; H, 7.45. Found: C, 73.22; H, 7.56. IR (solid state): ῦ/cm
-1 = 3073w, 3058w, 
3005w, 2950w, 2924m, 2880w, 2852m, 1584m, 1564w, 1468s, 1432s, 1421m-sh, 1385w, 1360w, 
1306w, 1268m, 1258m, 1242w, 1200s (νO-Ar), 1183m-sh, 1161w-sh, 1125m, 1094m, 1075m, 1041m, 
1026m, 1009w, 938w, 914w, 870s (νP-O), 848m, 833s, 821s, 806s, 772s, 757s, 744s, 731s, 693s, 683s-
sh. 1H NMR (CDCl3): δ/ppm = 7.64–7.58 (m, 4H, C11-H), 7.46–7.42 (m, 7H, C5-H + C12-H + C13-
H), 7.31 (dt, 3JHH = 15.4 Hz, 
4
JHH = 1.6 Hz, 1H, C7-H), 7.10 (dd, 
3
JHH = 8.1 Hz, 
4
JHP = 2.6 Hz, 1H, C8-
H), 7.06 (t, 3JHH = 7.3 Hz, 1H, C6-H), 0.81 (s, 9H, C1-H), 0.14 (s, 1H, C3-H). 
13C{1H} NMR (CDCl3): 
δ/ppm = 162.3 (d, 2JCP = 9 Hz, C9), 140.0 (d, 
1
JCP = 17 Hz, C10), 136.8 (C5), 131.7 (d, 
2
JCP = 23 Hz, 
C11), 130.8 (d, 4JCP = 2 Hz, C7), 130.0 (C13), 128.5 (d, 
3
JCP = 7 Hz, C12), 127.2 (d, 
3
JCP = 3 Hz, C4), 
121.7 (C6), 116.0 (d, 3JCP = 23 Hz, C8), 27.1 (C1), 17.7 (C2), -4.4 (C3). 
31P{1H} NMR (CDCl3): δ/ppm 
= 108.3. 29Si{1H} NMR (CDCl3): δ/ppm = 3.3. 
 
F. Synthesis of [RuCl2(η
6
-p-cymene){κP-Ph2PO(2-C6H4(SiMe2
t
Bu))}], 5. 
Chart 6. Structure of 5 (numbering refers to carbon atoms). 
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In a 25 mL Schlenk tube, [RuCl2(η
6-p-cymene)]2 (66 mg, 0.11 mmol) and Ph2P(O(2-C6H4SiMe2
tBu)) 
(111 mg, 0.283 mmol) were dissolved in CH2Cl2 (6 mL). The resulting red solution was stirred at 
ambient temperature for 14 hours and the progress of reaction was checked by TLC. Volatiles were 
removed under vacuum and the resulting red oily residue was triturated and suspended in hexane (20 
mL). The suspension was filtered and the red solid was washed with hexane and dried under vacuum 
(40 °C). Yield: 129 mg, 86%. The title compound is soluble in DMSO and chlorinated solvents, poorly 
soluble in EtOH and Et2O and insoluble in hexane and H2O. Crystals suitable for X-ray analysis were 
obtained from a CHCl3 solution of 5 layered with either hexane or heptane, and settled aside at -20 °C. 
Anal. calcd. for C34H43Cl2OPRuSi: C, 58.44; H, 6.20; Cl, 10.15. Found: C, 58.32; H, 6.12; Cl, 9.97. IR 
(solid state): ῦ/cm-1 = 3063w, 3041w, 2955m, 2925m, 2882w, 2853w, 1590w, 1568w, 1542w, 1469m, 
1435m, 1427m, 1378w, 1359w, 1322w, 1292w, 1273w, 1262w, 1255w, 1185s (νO-Ar), 1130m, 1096s, 
1078m, 1058w, 1037w, 1006w, 975w, 936w, 909w, 885s (νP-O), 859w-sh, 835m, 821s, 807s, 776m, 
758s, 737s, 722w, 705m-sh, 696s, 687s-sh. 1H NMR (CDCl3): δ/ppm =  7.92 (pseudo-t, 
3
JHH = 
3
JHP = 8 
Hz, 4H, C9-H), 7.62 (d, 3JHH = 8.3 Hz, 1H, C13-H), 7.52 (d, 
3JHH = 7.6 Hz, 1H, C16-H), 7.39–7.28 (m, 
6H, C10-H + C11-H), 7.19 (dt, 3JHH = 7.7 Hz, 
4JHH = 1.6 Hz, 1H, C14-H), 7.04 (t, 
3JHH = 7.2 Hz, 1H, 
C15-H), 5.39 (d, 3JHH = 6.2 Hz, 2H, C4-H), 5.33 (d, 
3
JHH = 6.0 Hz, 2H, C3-H), 2.56 (hept, 
3
JHH = 6.9 
Hz, 1H, C6-H), 1.67 (s, 3H, C1-H), 1.08 (s, 9H, C20-H), 0.91 (d, 3JHH = 7.0 Hz, 6H, C7-H), 0.40 (s, 
6H, C18-H). 13C{1H} NMR (CDCl3): δ/ppm = 158.2 (d, 
2
JCP = 4 Hz, C12), 137.5 (C16), 135.5 (d, 
1
JCP 
= 31 Hz, C8), 132.6 (d, 2JCP = 11 Hz, C9), 131.0 (C11), 130.9 (d, 
4
JCP = 2 Hz, C14), 127.7 (d, 
3
JCP = 11 
Hz, C10), 126.0 (d, 3JCP = 7 Hz, C17), 122.6 (C15), 122.0 (d, 
3
JCP = 10 Hz, C13), 110.6 (C5), 97.2 
(C2), 91.1 (C3), 87.4 (C4), 30.3 (C6), 27.5 (C20), 21.7 (C7), 18.1 (C19), 18.0 (C1), -3.5 (C18). 
31P{1H} NMR (CDCl3): δ/ppm = 120.3. 
29Si{1H} NMR (CDCl3): δ/ppm = 3.0 
 
G. Synthesis of [Ru(C2O4)(η
6
-p-cymene){κP-Ph2PO(2-C6H4(SiMe2
t
Bu))}], 6. 
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Chart 7. Structure of 6 (numbering refers to carbon atoms). 
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In a 25 mL Schlenk tube, freshly prepared [Ru(C2O4)(η
6-p-cymene)(H2O)] (114 mg, 0.334 mmol) and 
Ph2P(O(2-C6H4SiMe2
tBu)) (170 mg, 0.433 mmol) were dissolved in CH2Cl2 (5 mL). The reaction 
mixture was stirred at ambient temperature, affording a yellow-orange solution in 30’. After 18 hours, 
the progress of reaction was checked by TLC and volatiles were removed under vacuum. The residue 
was suspended in Et2O (20 mL) and the suspension was filtered. The resulting golden yellow solid was 
washed with Et2O and dried under vacuum (40 °C). Yield: 206 mg, 86%. The title compound is soluble 
in DMSO, EtOH and chlorinated solvents, insoluble in Et2O, hexane and H2O. X-ray quality crystals of 
6hexane were obtained from a CH2Cl2 solution of 2 layered with hexane and settled aside at -20 °C. 
Anal. calcd. for C36H43O5PRuSi: C, 60.40; H, 6.05. Found: C, 60.31; H, 5.96. IR (solid state): ῦ/cm
-1 = 
3058w, 2956w, 2928w, 2856w, 1697s, 1674s and 1666s-sh (νC=O), 1586w, 1564w, 1471m, 1434m-sh, 
1427m, 1360s, 1257w, 1180s (νO-Ar), 1128m, 1100m, 1074m, 1036w, 1008w, 937w, 892s (νP-O), 835m, 
822m, 807m, 778m, 764m, 739s, 710m-sh, 697s. 1H NMR (CDCl3): δ/ppm = 7.63-7.53 (m, 5H, C9-H 
+ C13-H), 7.45 (dt, 3JHH = 7.7 Hz, 
4
JHH = 1.4 Hz, 1H, C14-H), 7.41–7.31 (m, 7H, C10-H + C11-H + 
C16-H), 7.22 (t, 3JHH = 7.3 Hz, 1H, C15-H), 5.31 (d, 
3
JHH = 5.8 Hz, 2H, C3-H/C4-H), 5.11 (d, 
3
JHH = 
5.9 Hz, 2H, C3-H/C4-H), 2.26 (hept, 3JHH = 6.6, 1H, C6-H), 1.79 (s, 3H, C1-H), 1.16 (d, 
3JHH = 6.9 Hz, 
6H, C7-H), 1.06 (s, 9H, C20-H), 0.40 (s, 6H, C18-H). 13C{1H} NMR (CDCl3): δ/ppm = 165.4 (C21), 
159.2 (C12), 137.8 (C16), 133.9 (d, 1JCP = 47 Hz, C8), 131.7 (C11), 131.1 (C14), 131.0 (d, 
2
JCP = 12 
Hz, C9), 128.9 (d, 3JCP = 11 Hz, C10), 123.5 (C15), 121.6 (d, 
3
JCP = 10 Hz, C13), 111.6 (C5), 99.5 
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(C2), 87.6 (C3/C4), 87.3 (d, 2JCP = 3.7 Hz, C3/C4), 46.0 (C20), 27.3 (C6), 22.4 (C7), 18.3 (C1/C19), 
18.0 (C1/C19), 8.8 (C18). 31P{1H} NMR (CDCl3): δ/ppm = 124.3. 
29Si{1H} NMR (CDCl3): δ/ppm = 
3.4.  
 
Stability studies in DMSO/water solutions. 
General features (see Supporting Information for details). Ruthenium complexes were dissolved in 
DMSO-d6/D2O 9:1 v/v (0.8 mL; [Ru] = 1.5·10
-2 mol·L-1). An aliquot of the resulting solution (0.40 mL) 
was transferred into a NMR tube, maintained at 37°C for 72 hours and analyzed by NMR as a function 
of time. The remaining solution was diluted up to 4.0 mL with DMSO/H2O 9:1 v/v (final [Ru] = 1.5·10
-
3 mol·L-1), maintained at 37 °C for 72 hours and its conductivity was measured as a function of time. 
Both NMR and conductivity measurements were performed upon brief cooling to ambient temperature, 
then Ru-containing solutions were heated again at 37°C. Dimethyl sulfone (5.5·10-3 mol·L-1) was used 
as a reference for 1H NMR spectra (δ/ppm = 2.97 (s, 6H) in DMSO-d6/D2O 9:1 v/v). Molar 
conductivity (Λm) was calculated with reference to the starting material. Percent values of compounds 
in solution are based on 1H NMR spectroscopy and refer to identified compounds only. NMR signals in 
braces {} indicate superimpositions with other species. 
 
Chloride/solvent exchange experiments. 
General procedures. Solutions of RAPTA-C and [RuCl2(η
6-p-cymene)(κP-PPh3)] (Ru-PPh3) in D2O, 
CD3OD or CD3OD:D2O 9:1 v/v were analyzed by 
1H/35Cl/31P NMR spectroscopy and conductivity 
measurements. The subsequent addition of 1.0 eq. of AgNO3 was performed from a 0.2 M solution of 
AgNO3 in CD3OD:D2O 9:1 v/v. Freshly-prepared solutions of RAPTA-C, Ru-PPh3 and 1-3 in DMSO-
d6:D2O 9:1 v/v (cRu = 1.5·10
-2 mol·L-1) were analysed by 1H/35Cl/31P NMR spectroscopy. 1H and 31P 
NMR spectra were then repeated after the addition of NaCl (cNaCl = 0.15 mol·L
-1). 
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A. 
35
Cl NMR reference data. 
NaCl. 35Cl NMR (D2O, acq. time 1 min): δ/ppm = 0 (∆ν1/2 = 40 Hz). 
35Cl NMR (CD3OD, acq. time 1 
min): δ/ppm = -28.3 (∆ν1/2 = 1.7·10
2 Hz). 35Cl NMR (DMSO-d6:D2O 9:1, c = 0.11 mol·L
-1, acq. time 5 
min): δ/ppm = 46.4 (∆ν1/2 = 5.8·10
2 Hz). 35Cl NMR (DMSO-d6:D2O 9:1, c = 1.5·10
-2 mol·L-1, acq. time 
30 min): δ/ppm = 48.5 (∆ν1/2 = 5.2·10
2 Hz). [Et3NH]Cl. 
35Cl NMR (CD3OD, acq. time 1 min): δ/ppm = 
-22.7 (∆ν1/2 = 2.3·10
2 Hz). 35Cl NMR (CDCl3, acq. time 5 min): δ/ppm = 8.4 (∆ν1/2 = 1.3·10
3 Hz). 
B. [(RuCl2(η
6
-p-cymene)(PTA)] (RAPTA-C).  
Chart 8. Structures of RAPTA-C (left) and solvato-complex formed by Cl-abstraction with AgNO3 
(right) (numbering refers to carbon atoms). 
  
Cl
Ru
Solv P N
N
N
25
34
16
7
8
9
3'4'
7'
NO3
 
 
D2O. Orange solution. 
1H NMR: δ/ppm = 6.05 (d, J = 5.8 Hz), 5.96 (d, J = 5.9 Hz), 5.89 (d, J = 5.5 
Hz), 5.84 (m-br), 5.79 (d, J = 5.5 Hz), 4.60 (s), 4.57 (s), 4.33 (s), 4.31 (s), 4.28 (s), 4.22 (s), 2.59 (m), 
2.10 (s), 2.03 (s), 1.99 (m), 1.24–1.17 (m). 31P{1H} NMR: δ/ppm = -23.0, -32.6, -34.1, -35.1 (major). 
35Cl NMR (acq. time 1 min): δ/ppm = 0.49 (∆ν1/2 = 35 Hz). 
CD3OD. Orange-red solution. 
1H NMR: δ/ppm = 5.72 (d, 3JHH = 5.5 Hz, 2H, C3-H/C4-H), 5.68 (d, 
3
JHH 
= 5.7 Hz, 2H, C3-H/C4-H), 4.57 (s, 6H, C9-H), 4.31 (s, 6H, C8-H), 2.66 (hept, 3JHH = 6.6 Hz, 1H, C6-
H), 2.00 (s, 3H, C1-H), 1.21 (d, 3JHH = 6.9 Hz, 6H, C7-H). 
31P{1H} NMR (CD3OD): δ/ppm = -36.4. 
CD3OD:D2O 9:1 v/v. Orange-red solution. Λm (c = 1.5·10
-3 mol·L-1) = 35 S·cm2·mol-1. 1H NMR: a 
single set of signals was observed, with negligible chemical shift variation with respect to that in 
CD3OD. 
31P{1H} NMR: δ/ppm = -36.1. 35Cl NMR (acq. time 10 min): no signal. 
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CD3OD:D2O 9:1 v/v + AgNO3 (1 eq.). Yellow-orange solution + AgCl precipitate. Λm (c = 1.5·10
-3 
mol·L-1) = 81 S·cm2·mol-1. NMR data indicate quantitative formation of [(η6-p-
cymene)RuCl(Solv)(PTA)]+. 1H NMR: δ/ppm = 6.05 (d, 3JHH = 5.9 Hz, 1H), 5.96 (d, 
3
JHH = 6.1 Hz, 
1H), 5.80 (d, 3JHH = 5.5 Hz, 1H), 5.76 (d, 
3
JHH = 5.5 Hz, 1H, C3-H + C3-H’ + C4-H + C4’-H); 4.63 (s, 
6H, C9-H), 4.41–4.29 (m, 6H, C8-H), 2.65 (hept, 3JHH = 6.5 Hz, 1H, C6-H), 2.07 (s, 3H, C1-H), 1.27 
(d, 3JHH = 6.9 Hz, 3H, C7-H), 1.24 (d, 
3
JHH = 6.4 Hz, 3H, C7’-H). 
31P{1H} NMR: δ/ppm = -34.9. 
DMSO-d6:D2O 9:1 v/v. Orange solution. Λm (c = 1.5·10
-3 mol·L-1) = 24 S·cm2·mol-1. 1H NMR: δ/ppm 
= 5.72 (d, 3JHH = 5.7 Hz, 2H, C3-H/C4-H), 5.69 (d, 
3JHH = 5.7 Hz, 2H, C3-H/C4-H), 4.41 (s, 6H, C9-
H), 4.14 (s, 6H, C8-H), 1.86 (s, 3H, C1-H), 1.09 (d, 3JHH = 6.8 Hz, 6H, C7-H). 
31P{1H} NMR: δ/ppm = 
-34.1. 35Cl NMR (acq. time 30 min): no signal.  
DMSO-d6:D2O 9:1 v/v + NaCl. 
1H NMR and 31P{1H} NMR: a single set of signals was observed, 
identical to that without NaCl. 
C. [RuCl2(η
6
-p-cymene)(κP-PPh3)] (Ru-PPh3). 
CD3OD:D2O 9:1 v/v. Orange-brown solution. Λm (c = 1.5·10
-3 mol·L-1) = 68 S·cm2·mol-1. 1H NMR: 
δ/ppm = 7.83–7.76 (m, 4H), 7.53–7.38 (m, 6H), 5.33 (d, 3JHH = 6.1 Hz, 2H), 5.21 (d, 
3
JHH = 5.9 Hz, 
2H), 2.72–2.62 (m, 1H), 1.89 (s, 3H), 1.09 (d, 3JHH = 6.8 Hz, 6H). 
31P{1H} NMR: δ/ppm = 24.5. 35Cl 
NMR (acq. time 10 min): no signal.  
CD3OD:D2O 9:1 v/v + AgNO3 (1 eq.). Yellow solution + precipitate. Λm (c = 1.5·10
-3 mol·L-1) = 103 
S·cm2·mol-1. Two major sets of signals, in ca. 1:1 ratio, were identified, along with other minor 
products. First set (identical to that of Ru-PPh3). 
1H NMR: δ/ppm = 7.82–7.76 (m, 4H), 7.54–7.38 (m, 
6H), 5.36 (d, 3JHH = 6.2 Hz, 2H), 5.21 (d, 
3JHH = 5.7 Hz, 2H), 2.69 (m, 
3JHH = 7.1 Hz, 1H), 1.89 (s, 3H), 
1.11 (d, 3JHH = 6.9 Hz, 6H). 
31P{1H} NMR: δ/ppm = 24.9. Second set. 1H NMR: δ/ppm = 7.70-7.63 
(m), {7.54–7.38 (m)}, 5.70 (s-br, 2H), 5.31 (s-br, 1H), 5.15 (s-br, 1H), 2.79 (hept, 3JHH = 6.4 Hz, 1H), 
1.82 (s-br, 3H), 1.29 (s-br, 6H). 31P{1H} NMR: δ/ppm = 31.2 (m-br). 
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DMSO-d6:D2O 9:1 v/v. 
1H NMR: δ/ppm = 7.77–7.66 (m, 6H), 7.46–7.35 (m, 9H), 5.27 (d, J = 5.9 Hz, 
2H), 5.21 (d, J = 5.6 Hz, 2H), 1.74 (s, 3H), 0.93 (d, J = 6.8 Hz, 6H). 31P{1H} NMR: δ/ppm = 24.2. 35Cl 
NMR (acq. time 30 min): no signal.  
DMSO-d6:D2O 9:1 v/v + NaCl. 
1H NMR and 31P{1H} NMR: a single set of signals was observed, 
identical to that without NaCl. 
D. [RuCl2(η
6
-p-cymene){κP-Ph2P(4-C6H4O-R)}], R = OSiMe2
t
Bu (1), Br (2), OCOCHCl2 (3). 
R = OSiMe2
t
Bu, 1. DMSO-d6:D2O 9:1 v/v. 
1H NMR: δ/ppm = 7.73–7.66 (m, 4H), 7.60 (t, J = 9.2 Hz, 
2H), 7.44–7.33 (m, 6H), 6.85 (d, J = 7.9 Hz, 2H), 5.27 (d, J = 6.0 Hz, 2H), 5.20 (d, J = 5.7 Hz, 2H), 
1.74 (s, 3H), 1.00–0.85 (m, 15H), 0.18 (s, 6H). 31P{1H} NMR (DMSO-d6:D2O 9:1): δ/ppm = 23.2. 
35Cl 
NMR (acq. time 30 min): no signal.  
DMSO-d6:D2O 9:1 v/v + NaCl. 
1H NMR and 31P{1H} NMR: a single set of signals was observed, 
identical to that without NaCl. 
R = Br, 2. DMSO-d6:D2O 9:1 v/v. 
1H NMR: δ/ppm = 7.74–7.67 (m, 4H), 7.65 (t, J = 9.0 Hz, 2H), 7.54 
(d, J = 7.6 Hz, 2H), 7.50–7.40 (m, 6H), 5.30 (d, J = 6.0 Hz, 2H), 5.23 (d, J = 5.8 Hz, 2H), 1.74 (s, 3H), 
0.93 (d, J = 6.9 Hz, 6H). 31P{1H} NMR: δ/ppm = 24.5. 35Cl NMR (acq. time 30 min): no signal.  
DMSO-d6:D2O 9:1 v/v + NaCl. 
1H NMR and 31P{1H} NMR: a single set of signals was observed, 
identical to that without NaCl. 
R = OCOCHCl2, 3. DMSO-d6:D2O 9:1 v/v. 
1H NMR: δ/ppm = 7.72–7.65 (m, 4H), 7.54 (t, J = 8.8 Hz, 
2H), 7.46–7.32 (m, 6H), 6.77 (d, J = 7.6 Hz, 2H), 6.37 (s, 1H), 5.26 (d, J = 5.3 Hz, 2H), 5.17 (d, J = 4.7 
Hz, 2H), 1.73 (s, 3H), 0.94 (d, J = 6.5 Hz, 6H). 31P{1H} NMR (DMSO-d6:D2O 9:1): δ/ppm = 23.1. 
DMSO-d6:D2O 9:1 v/v + NaCl. 
1H NMR and 31P{1H} NMR: a single set of signals was observed, 
identical to that without NaCl. 
 
X-ray crystallography. 
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Crystal data and collection details for 3·CH3COCH3, 4, 5 and 6·C6H14 are reported in Table 16S. Data 
were recorded on a Bruker APEX II diffractometer equipped with a CCD detector using Mo–Kα 
radiation. Data were corrected for Lorentz polarization and absorption effects (empirical absorption 
correction SADABS).51 The structures were solved by direct methods and refined by full-matrix least-
squares based on all data using F2.52 Hydrogen atoms were fixed at calculated positions and refined by 
a riding model. All non-hydrogen atoms were refined with anisotropic displacement parameters. 
 
In vitro cytotoxicity studies. 
Reagents. Eagle’s minimum essential medium (MEM) was purchased from Sigma Aldrich, while 
trypsin-EDTA, penicillin, streptomycin, sodium pyruvate, non-essential amino acid solution, fetal calf 
serum (FCS), plates and Petri dishes were purchased from EuroClone. The compounds were dissolved 
in dimethyl sulfoxide (DMSO) before performing each experiment. The maximal concentration utilized 
was 50 µM, due to limited water solubility; cisplatin was tested up to 100 µM.Errore. Il segnalibro non è definito. 
The same volume of solvent was added to control conditions and did not exceed 0.25% v/v.  
Cell culture. Human triple negative cancer cell line MDA-MB-231, human ovarian carcinoma cell line 
A2780 and Human Skin Fibroblasts (HSF) were cultured in MEM supplemented with 10% FCS, non-
essential amino acids, and penicillin/streptomycin at 37°C in a humidified atmosphere (5% CO2 and 
95% air). 
Cell viability assay. Sulphorhodamine B (SRB) assay was performed to assess the cell viability after 
treatments. 5x103 cells/well were seeded in a 96-well tray in triplicate. After 24h of incubation, the 
cells were treated with different concentrations of compounds. SRB assay were performed after 48h 
according to the method of Skehan et al.53 
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Cell cycle analysis. Cell cycle analysis was performed as previously described.54 In brief, cells were 
seeded (250,000/35 mm petri dish) and incubated with DMEM supplemented with 10% FCS; 24 h later 
the medium was replaced with one containing 10% FCS in the presence or absence (control) of 50 µM 
of complex 3, and the incubation was continued for a further 24 h. At the end of this incubation period 
cells were re-suspended with permeabilizing buffer (NaCl 100 mM, TRIS pH 7.4 150 mM; CaCl2 1 
mM; MgCl2 0.5 mM; NP-40 0.1% containing 5 mM propidium iodide and 40 mg/ml of RNAse A) and 
the DNA nuclear content was analyzed with FACScan™ flow cytometer and BD CellQuest™ (both 
from BD Biosciences, San Jose, CA, USA). 
Statistical analysis. Experimental data are expressed as mean ± S.D. The effects of the complexes 
versus control were analyzed by two-tailed Student’s t test for unpaired data. The concentration of 
compounds required to reduce cell viability by 50% (IC50) was calculated by nonlinear regression curve 
(GraphPad Prism, Version 5.01). 
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